Regenerative Therapies for Parkinson’s Disease: An Update.
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 357, doi. 10.1007/s40259-018-0294-1
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2018 AND VI 32 AND IP 4
Results: 10
1
2
Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study.
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 367, doi. 10.1007/s40259-018-0293-2
- By:
- Publication type:
- Article
3
Pegvaliase: First Global Approval.
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 391, doi. 10.1007/s40259-018-0292-3
- By:
- Publication type:
- Article
4
Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 311, doi. 10.1007/s40259-018-0291-4
- By:
- Publication type:
- Article
5
Spherical Nucleic Acid Nanoparticles: Therapeutic Potential.
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 297, doi. 10.1007/s40259-018-0290-5
- By:
- Publication type:
- Article
6
Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies.
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 339, doi. 10.1007/s40259-018-0289-y
- By:
- Publication type:
- Article
7
Determination of Similarity Margin in Comparative Clinical Studies to Support the Development of Biosimilar Products of Neupogen<sup>®</sup> (Filgrastim, Granulocyte Colony-Stimulating Factor [G-CSF]).
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 325, doi. 10.1007/s40259-018-0288-z
- By:
- Publication type:
- Article
8
The End of Phase 3 Clinical Trials in Biosimilars Development?
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 319, doi. 10.1007/s40259-018-0287-0
- By:
- Publication type:
- Article
9
Oligonucleotide-Based Therapies for Inflammatory Bowel Disease.
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 331, doi. 10.1007/s40259-018-0286-1
- By:
- Publication type:
- Article
10
Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS).
- Published in:
- BioDrugs, 2018, v. 32, n. 4, p. 377, doi. 10.1007/s40259-018-0285-2
- By:
- Publication type:
- Article